Cancer Patients Treated With Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-0253
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Thyroid Dysfunction in Patients Treated With Sunitinib or Sorafenib

Clinical Genitourinary Cancer
OncologyUrology
2012English

Hypothyroidism Side Effect in Patients Treated With Sunitinib or Sorafenib: Clinical and Structural Analyses

PLoS ONE
Multidisciplinary
2016English

Reply to Influenza Vaccination in Patients With Cancer

Cancer
Cancer ResearchOncology
2017English

Acquired Immune Responses to the Seasonal Trivalent Influenza Vaccination in COPD

Clinical and Experimental Immunology
AllergyImmunology
2019English

Vaccination With Dengue Virus-Like Particles Induces Humoral and Cellular Immune Responses in Mice

Virology Journal
VirologyInfectious Diseases
2011English

Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Immune Responses to Polyclonal T-Cell Vaccination in Patients With Progressive Multiple Sclerosis

Journal of Immunotoxicology
ToxicologyImmunology
2016English

Immune Responses to Avian Influenza Viruses

Journal of Immunology
AllergyImmunology
2019English

Cellular and Mucosal Immune Responses Following Vaccination With Inactivated Mutant of Escherichia Coli O157:H7

Scientific Reports
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy